AI Article Synopsis
- A study analyzed the outcomes of intravitreal injections of ranibizumab in 103 patients undergoing pars plana vitrectomy for diabetic vitreous hemorrhage.
- Patients who received ranibizumab had a significantly lower rate of recurrent hemorrhage (6.1%) compared to the control group (24.3%), and better visual acuity at the 6-month follow-up.
- The study concludes that ranibizumab is effective in preventing postoperative complications without affecting intraocular pressure.
Article Abstract
To evaluate the outcomes and complications of intravitreal injections of ranibizumab in patients during pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. This retrospective, observational, comparative study included 103 patients (103 eyes) who underwent pars plana vitrectomy for treatment of diabetic vitreous hemorrhage. Sixty-six patients received an intravitreal injection of 0.05 mg (0.05 cc) of ranibizumab at the end of surgery. Main outcome measures were the occurrence of recurrent early vitreous hemorrhage, reoperation, intraocular pressure, best corrected visual acuity. Mean follow-up time was 6 months. The rate of rebleeding in the intravitreal ranibizumab (IVR) group was 6.1% (4 eyes), which is significantly lower than the control group (24.3%, 9 eyes, P < .01). The incidence of postoperative diabetic vitreous hemorrhage (PDVH) was significantly lower in the IVR group than the control group, OR=0.26, 95% CI= (0.06, 0.95). Visual acuity 6 months after operation was better in IVR group (P<.01) There was no difference in mean intraocular pressure between the 2 groups (P=.56). The present clinical study suggests that intravitreal injection of ranibizumab is effective in the prevention of postoperative diabetic vitreous hemorrhage in eyes undergoing pars plana vitrectomy for the treatment of diabetic vitreous hemorrhage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531093 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000015735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity.
Ophthalmol Retina
January 2025
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Canada. Electronic address:
Purpose: Laser photocoagulation (LPC) has been a traditional treatment for retinopathy of prematurity (ROP). However, intravitreal anti-VEGF agents such as bevacizumab and ranibizumab (IVR) have also been increasingly used. This meta-analysis aims to rigorously compare IVR to LPC in the treatment of ROP.
View Article and Find Full Text PDFPurpose: The light adjustable lens (LAL) (RxSight, Aliso Viejo, CA) is a premium intraocular lens that allows for correction of residual refractive error and astigmatism following implantation. Herein, we describe the surgical approach and evaluate the visual outcomes of patients following scleral fixation of the LAL.
Methods: Retrospective, single-surgeon surgical case series of 3 patients (3 eyes) with intraocular lens complications, who underwent combined pars plana vitrectomy and sutureless needle assisted intrascleral haptic fixation of the LAL between April 2022, to August 2023.
Vitreous cavity lavage with a bended-needle system for postoperative vitreous cavity hemorrhage.
Retina
January 2025
Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Purpose: To present a novel bended-needle drainage system in vitreous cavity lavage (VCL) for postoperative vitreous cavity hemorrhage (POVCH).
Methods: This retrospective case series include all patients with POVCH who received VCL with the bended-needle drainage system at ophthalmology department of Peking Union Medical College Hospital from January 2022 to May 2024. Patients adopted a supine position that allows preparation and draping.
Complications After Incisional/Excisional Minimally Invasive Glaucoma Surgery-An Update and Literature Review.
Semin Ophthalmol
January 2025
Glaucoma Service, LV Prasad Eye Institute, Hyderabad, India.
Purpose: To discuss comprehensively the varied complications after stent-less incisional or excisional minimally invasive glaucoma surgery (MIGS).
Method: A review of reported complications after stent-less MIGS procedures including gonioscopy-assisted transluminal trabeculotomy (GATT), bent needle goniectomy (BANG), Kahook-dual blade goniotomy, and microincisional trabeculectomy (MIT) published between 2014-2024, were analyzed and summarized.
Results: Apart from hyphema, peripheral anterior synechiae, and intraocular pressure spikes, other vision-threatening complications like cyclodialysis, Descemet's detachment, corneal edema, iridodilalysis, vitreous loss or vitreous hemorrhage can also occur intra- or postoperatively after any incisional or excisional MIGS procedures.
Coats disease presenting with vitreous hemorrhage and neovascular glaucoma.
Am J Ophthalmol Case Rep
March 2025
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, 60612, USA.
Purpose: To describe a patient with Coats disease with an atypical presentation of neovascular glaucoma and vitreous hemorrhage.
Observations: A 15-year-old male presented with five days of pain, redness, and swelling and was found to have neovascular glaucoma in his right eye. Further evaluation revealed Coats disease stage 3AI with a subtotal exudative retinal detachment inferiorly, telangiectatic vessels, and vitreous hemorrhage.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!